本帖最后由 maicon08 于 2023-4-28 15:12 编辑 ! J$ D+ s1 G3 m' n3 ~
& y7 t7 {; U8 F$ `一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。% k: N- N; O& E" y8 ~* }
( y0 ~- U& {+ N2 X' k2 ?
https://www.163.com/dy/article/I3BTTPRD053438SI.html+ \. o4 D3 i1 w$ L+ o0 Y J! p/ l2 [
" N3 a+ L6 C: X; k7 f9 a
' m5 G/ l- y9 r3 z8 b* h在研疗法-免疫治疗
1 x3 M L* T5 @# @8 |2 N T% jDevelopmental Therapeutics—Immunotherapy( y: E6 [9 t( e0 q$ g( P
1 Y/ V4 y% P2 N+ |* Q& x摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心
# U. G/ d; f% W# A8 g/ T7 A
在研疗法-分子靶向药物和肿瘤生物学
( h" y6 b* {, [3 g1 B8 X( L Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology * t- E# y H8 e1 `+ W
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心 4 p( c8 c Z/ V# A
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院 1 M W. P9 D2 t0 ]- u0 X- l* X& h
胃肠道肿瘤-结直肠癌和肛门癌
. r h. Z c6 f! [ Q7 Z Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 ; s; V, |& k* a% ?( z( ~, @# {
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary ) H! [( R) @6 `- j
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心
" b8 p ^9 C( Z' r6 p% q! o
妇科肿瘤 Gynecologic Cancer
% X- J9 `7 X& K/ r摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院 5 D4 l1 z. V% \+ ]) Q7 H0 c: F5 s" f
头颈肿瘤
3 h% W: y7 n9 q) J2 w Head and Neck Cancer
- m9 z3 \" o$ P, s. X3 j摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心
1 A7 A9 Z. d4 u' G" y
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心
' f$ Y$ w \. J- k% R8 T$ K3 B2 r
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 . S. e9 `' a: S5 W8 l F
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
% z3 j F4 p9 U( k+ ^摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心
" B$ W, `2 Q" a5 e5 V$ }
血液系统恶性肿瘤-浆细胞疾病
+ H! O, @. v, o4 b, I Hematologic Malignancies—Plasma Cell Dyscrasia
6 k/ a M, F- @+ o `7 H摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院
" _% a7 ~& |& t: R
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
- ^% g& Z1 L) F7 k U k Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
1 N6 t: n) Z% m1 k: M. W摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院 / @) ?( n8 Z0 P9 g9 K
肺癌-转移性非小细胞肺癌) Q! ^5 F6 Y8 ~' J, z C% ]
Lung Cancer—Non-Small Cell Metastatic
/ d3 ^. Y. D" u* V摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
+ e" l* \! ]* w+ P0 T- @
+ y; U" x& l; W S& d u% E
摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院
" b, R+ m0 [3 v( ?# d
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院
+ f5 _( Y* n* E: r$ g
黑色素瘤/皮肤癌
9 `8 S/ k1 j* G2 t Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院 - v- k2 P* D+ i6 V' ~& F
快速摘要报告8 k4 T% c5 b/ ?9 j+ a$ q
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
1 H+ N& P4 B5 `3 {7 J
临床科学研讨会
) Z& g+ s3 V3 ?7 C Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
+ \/ Y$ m$ Q% `6 `1 e* \% V: X+ {$ j# t I( }0 b' {
| 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
